- Home
- SRTS vs ABOS Comparison
SRTS vs ABOS Comparison
Compare SRTS & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- ABOS
- Stock Information
- Founded
- SRTS 2010
- ABOS 1996
- Country
- SRTS United States
- ABOS United States
- Employees
- SRTS N/A
- ABOS N/A
- Industry
- SRTS Medical/Dental Instruments
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- ABOS Health Care
- Exchange
- SRTS Nasdaq
- ABOS Nasdaq
- Market Cap
- SRTS 75.5M
- ABOS 85.4M
- IPO Year
- SRTS 2016
- ABOS 2021
- Fundamental
- Price
- SRTS $3.39
- ABOS $1.36
- Analyst Decision
- SRTS Strong Buy
- ABOS Strong Buy
- Analyst Count
- SRTS 3
- ABOS 3
- Target Price
- SRTS $8.00
- ABOS $8.00
- AVG Volume (30 Days)
- SRTS 215.6K
- ABOS 254.2K
- Earning Date
- SRTS 08-07-2025
- ABOS 08-12-2025
- Dividend Yield
- SRTS N/A
- ABOS N/A
- EPS Growth
- SRTS N/A
- ABOS N/A
- EPS
- SRTS N/A
- ABOS N/A
- Revenue
- SRTS $37,564,000.00
- ABOS N/A
- Revenue This Year
- SRTS N/A
- ABOS N/A
- Revenue Next Year
- SRTS $33.38
- ABOS N/A
- P/E Ratio
- SRTS N/A
- ABOS N/A
- Revenue Growth
- SRTS 3.29
- ABOS N/A
- 52 Week Low
- SRTS $3.03
- ABOS $0.86
- 52 Week High
- SRTS $9.33
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- SRTS 39.05
- ABOS 47.95
- Support Level
- SRTS $3.08
- ABOS $1.35
- Resistance Level
- SRTS $3.45
- ABOS $1.60
- Average True Range (ATR)
- SRTS 0.20
- ABOS 0.10
- MACD
- SRTS 0.01
- ABOS -0.01
- Stochastic Oscillator
- SRTS 82.00
- ABOS 41.46
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.